234 related articles for article (PubMed ID: 26360252)
1. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
2. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
3. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
4. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
5. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK; Kaufmann AM; Riemer AB
Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
[TBL] [Abstract][Full Text] [Related]
6. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.
Da Silva DM; Woodham AW; Rijkee LK; Skeate JG; Taylor JR; Koopman ME; Brand HE; Wong MK; McKee GM; Salazar AM; Kast WM
Papillomavirus Res; 2015 Dec; 1():12-21. PubMed ID: 26665182
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
[TBL] [Abstract][Full Text] [Related]
9. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.
Trimble CL; Clark RA; Thoburn C; Hanson NC; Tassello J; Frosina D; Kos F; Teague J; Jiang Y; Barat NC; Jungbluth AA
J Immunol; 2010 Dec; 185(11):7107-14. PubMed ID: 21037100
[TBL] [Abstract][Full Text] [Related]
12. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
13. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
[TBL] [Abstract][Full Text] [Related]
15. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
[TBL] [Abstract][Full Text] [Related]
16. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
[TBL] [Abstract][Full Text] [Related]
17. Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1β -511 is associated with development of cervical carcinoma.
Dutta S; Chakraborty C; Mandal RK; Basu P; Biswas J; Roychoudhury S; Panda CK
Cancer Immunol Immunother; 2015 Jul; 64(7):843-51. PubMed ID: 25893807
[TBL] [Abstract][Full Text] [Related]
18. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
